- Home
- MBBC vs PLUR Comparison
MBBC vs PLUR Comparison
Compare MBBC & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBBC
- PLUR
- Stock Information
- Founded
- MBBC 1902
- PLUR 2001
- Country
- MBBC United States
- PLUR Israel
- Employees
- MBBC N/A
- PLUR N/A
- Industry
- MBBC Banks
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MBBC Finance
- PLUR Health Care
- Exchange
- MBBC Nasdaq
- PLUR Nasdaq
- Market Cap
- MBBC 31.7M
- PLUR 36.9M
- IPO Year
- MBBC N/A
- PLUR N/A
- Fundamental
- Price
- MBBC $11.48
- PLUR $3.80
- Analyst Decision
- MBBC
- PLUR Strong Buy
- Analyst Count
- MBBC 0
- PLUR 1
- Target Price
- MBBC N/A
- PLUR $12.00
- AVG Volume (30 Days)
- MBBC 5.6K
- PLUR 53.4K
- Earning Date
- MBBC 11-12-2025
- PLUR 11-12-2025
- Dividend Yield
- MBBC N/A
- PLUR N/A
- EPS Growth
- MBBC N/A
- PLUR N/A
- EPS
- MBBC 0.11
- PLUR N/A
- Revenue
- MBBC $7,299,708.00
- PLUR $1,326,000.00
- Revenue This Year
- MBBC N/A
- PLUR $97.38
- Revenue Next Year
- MBBC N/A
- PLUR $293.97
- P/E Ratio
- MBBC $102.67
- PLUR N/A
- Revenue Growth
- MBBC 7.77
- PLUR 121.74
- 52 Week Low
- MBBC $7.21
- PLUR $3.22
- 52 Week High
- MBBC $12.89
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- MBBC 62.24
- PLUR 48.43
- Support Level
- MBBC $11.35
- PLUR $3.60
- Resistance Level
- MBBC $11.70
- PLUR $4.12
- Average True Range (ATR)
- MBBC 0.18
- PLUR 0.38
- MACD
- MBBC 0.06
- PLUR 0.02
- Stochastic Oscillator
- MBBC 60.97
- PLUR 34.27
About MBBC Marathon Bancorp Inc. Common Stock
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.